Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h

Figures

• 

  Figure 1. Consolidated standards of reporting trails (CONSORT) flow chart of this secondary pre-specified sub-analysis. Shown is the analysis population, the number of patients with a primary efficacy outcome, the number of patients with a safety outcome, and the number of patients who developed electrocardiogram-diagnosed atrial fibrillation in each group

• 

  Figure 2. Atrial high-rate episodes (AHREs) characteristics by atrial high-rate episode duration. (A) Number of atrial high-rate episodes prior to at baseline. (B) Time from last adequate atrial high-rate episode to baseline by atrial high-rate episode duration in months. (C) Duration of the maximal atrial high-rate episode at baseline (longest single episode) in minutes and days. The apparent peak at 4 days (99 h) atrial high-rate episode duration is due to the fact that some manufacturers only store precise atrial high-rate episode durations up to 99 h, while other manufacturers and devices precisely capture atrial high-rate episode durations up to 9999 h. All graphs show separate distributions for each randomized group in the 2389 patients with adequate atrial high-rate episode. There were no differences between randomized groups

• 

  Figure 3. Cumulative incidence curves of the primary outcome and secondary outcomes incidence curves considering death competing event (Aalen–Johansen curve). (A) Primary outcome, a composite of stroke, systemic embolism, and cardiovascular death. (B) All-cause death and major bleeding. (C) Ischaemic stroke. (D) Ischaemic stroke or systemic embolism

• 

  Figure 4. Cumulative incidence curve from baseline to electrocardiogram-diagnosed atrial fibrillation considering death as competing event (Aalen–Johansen curve; P < .001). Survival curves are shown for patients with long atrial high-rate episode ≥24 h and shorter atrial high-rate episode split by randomized group